MBX Biosciences (MBX) Change in Account Payables (2023 - 2026)

MBX Biosciences has disclosed Change in Account Payables across 4 years of filings, most recently posting $4.0 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at $4.0 million, up 353.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.1 million (up 63.05% YoY), and the FY2025 annual result was -$2.5 million, down 162.54% from the prior year.
• Change in Account Payables came in at $4.0 million for Q1 2026 at MBX Biosciences, up from -$861000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $4.0 million in Q1 2026 to a low of -$2.0 million in Q3 2025.
• The 4-year median for Change in Account Payables is $526500.0 (2024), against an average of $513300.0.
• Across the five-year window, Change in Account Payables plunged 429.96% in 2025 and surged 353.96% in 2026, its largest moves.
• MBX Biosciences' Change in Account Payables stood at -$310000.0 in 2023, then jumped by 308.06% to $645000.0 in 2024, then tumbled by 233.49% to -$861000.0 in 2025, then jumped by 561.32% to $4.0 million in 2026.
• The last three Change in Account Payables figures came in at $4.0 million (Q1 2026), -$861000.0 (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.